Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > EC probe sets precedent for cancer drug price reduction
  • News

EC probe sets precedent for cancer drug price reduction

  • 1 March 2021
  • Janet Fricker
EC probe sets precedent for cancer drug price reduction
Total
0
Shares
0
0
0
0
0

The European Commission (EC) has made commitments offered by Aspen Pharmacare Holding, to reduce prices for six critical cancer medicines by around two thirds, legally binding. In the acceptance agreement (10 February) Aspen will additionally retrospectively reimburse member states by excess amounts paid since 1 October 2019 and ensure continual off-patent medicine supplies for a significant period.

“Today’s decision gives a strong signal to other dominant pharmaceutical companies not to engage in abusive pricing practices to exploit our health systems,” said Margretje Vestager, the European Competition Commissioner, in a statement.

In May 2017, the EC opened a formal investigation around concerns Aspen Pharmacare Holdings, a company headquartered in Durban, South Africa, was engaging in excessive pricing of six haematological cancer medicines containing the active pharmaceutical ingredients chlorambucil, melphalan, mercaptopurine, tioguanine and busulfan. Aspen, who had acquired facilities to manufacture these ingredients after patent protection had expired and was the only supplier, adopted a ‘price gouging’ policy where it imposed unjustified price increases of up to several hundred percent. The medicines had been off-patent for 50 years, with the effect that any R&D investments had already been recouped.

The EC believed Aspen’s behaviour to be in breach of the EU’s antitrust rules (namely Article 102 of the Treaty on the Functioning of the European Union [TFEU] which prohibits the abuse of dominant market positions, and Article 54 of the European Economic Area [EEA] Agreement, which forbid imposition of unfair prices or trading conditions on customers). If found guilty of breaching EU rules Aspen could have faced a fine of up to 10% of its global turnover on top of a finding of wrongdoing. Article 9 of the antitrust rules, however, allows companies under EC investigation to offer commitments to address concerns.

Aspen offered the following commitments which the EC has now made legally binding:

  • To introduce an average price reduction across products of 73%.
  • 
To maintain reduced prices for 10 years and guarantee supply for at least five years.
  • After five years, should Aspen wish to cease commercialising any of the products it will make them available for sale to a third party.
  • Aspen will make a one-time payment to the relevant entities responsible for reimbursement of medicine.

Commenting on the agreement, the European Cancer Patient Coalition (ECPC), wrote in a press statement, “Through enforcement action and proposing a feasible solution to the competition concerns in the Aspen case, the Commission gives an example of how patients’ rights and needs should come before any vested industrial interest and creates a precedent for those who disrespect the EU values and laws that will have to deal with the consequences.”

The European Consumer Organisation (BEUC) Director General Monique Goyens said, “All pharma companies must now take note of this decision when negotiating drug prices with national healthcare systems. They should be fair for healthcare systems and consumers.”

The agreement holds in the European Economic Area (EEA), including EU member states together with UK, Iceland, Liechtenstein and Norway. It does not, however, include Italy. On 29 September 2016, the Italian Antitrust Authority fined Aspen €5 million for abusing its dominant position and fixing unfair prices for life saving cancer drugs following a complaint from the Italian consumer group Altroconsumo.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • antitrust rules
  • european commission
  • excessive pricing
  • off-patent
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Biology basic

Natural killers: a new tactical unit joins the cancer immunotherapy brigade

  • 25 February 2021
  • Adriana Albini
View Post
Next Article
  • Interviews to the Expert

Bridging the Age Gap in Breast Cancer: A treatment selection tool for the over-70s

  • 2 March 2021
  • Alberto Costa
View Post
You May Also Like
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Janet Fricker
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • CancerWorld issue #103 (May, 2025)
    • 11 May 2025
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
Article
  • Why Patient-Reported Outcomes are Rarely Used in Trials, and How We Change That
    • 27 May 2025
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
Social

Would you follow us ?

Contents
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
  • Adrian Gottschalk: Making a Difference for His Fellow Human Beings
    • 10 May 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.